In relation to JUP/Plakoglobin, a gene that produces the protein γ-catenin and is homologous to β-catenin [70], it was reported to be necessary for maintaining the “BCR-ABL1” genetic abnormality (through regulation of MYC and BIRC5/survivin) in B-ALL, being proposed as a potential therapeutic target [71]. This evidence concerns the gene JUP and precursor B-cell acute lymphoblastic leukemia.